Natera, Inc.
NTRA
Kedudukan dalam Saham
#409
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Harga Saham
$406.45
Modal Pasaran
$58.59B
Perubahan (1 hari)
1.76%
Perubahan (1 tahun)
115.51%
Negara
US
Perdagangan Natera, Inc. (NTRA)
Kategori
Healthcare
Nisbah P/E bagi Natera, Inc. (NTRA)
Nisbah P/E pada October 2026 TTM: -290.26
Menurut laporan kewangan dan harga saham terkini Natera, Inc., nisbah P/E semasa (TTM) ialah -290.26. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -16.57.
Sejarah nisbah P/E bagi Natera, Inc. dari 2012 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -290.26 | 179.96% |
| 2024 | -103.68 | 525.80% |
| 2023 | -16.57 | 129.58% |
| 2022 | -7.22 | -59.75% |
| 2021 | -17.93 | -48.91% |
| 2020 | -35.09 | 86.94% |
| 2019 | -18.77 | 198.53% |
| 2018 | -6.29 | 78.85% |
| 2017 | -3.52 | -44.11% |
| 2016 | -6.29 | -14.08% |
| 2015 | -7.32 | -94.29% |
| 2014 | -128.17 | 620.30% |
| 2013 | -17.79 | 2,308.87% |
| 2012 | -0.74 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 36.15 | -112.46% |
US
|
|
| 39.77 | -113.70% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -111.78% |
US
|
|
| 32.24 | -111.11% |
US
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.